Koppenhagen F J, Küpcü Z, Wallner G, Crommelin D J, Wagner E, Storm G, Kircheis R
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands.
Clin Cancer Res. 1998 Aug;4(8):1881-6.
Vaccination with tumor cells genetically engineered to produce interleukin (IL)-2 is an attractive strategy to enhance antitumor immune responses. The improved antitumor immunity upon vaccination with IL-2 gene-modified tumor cells may be due to the prolonged presence of the cytokine at the vaccination site. Because liposomes have been used for sustained delivery of a variety of agents, we compared the protective effect of vaccines consisting of IL-2 gene-modified B16 melanoma cells to that of vaccines composed of IL-2 liposomes and irradiated melanoma cells. The results indicate that both approaches equally protect against a lethal challenge with B16 melanoma cells. More than 20% of the protected animals developed vitiligo at the vaccination and/or tumor challenge site.
用经过基因工程改造以产生白细胞介素（IL）-2的肿瘤细胞进行疫苗接种是增强抗肿瘤免疫反应的一种有吸引力的策略。接种IL-2基因修饰的肿瘤细胞后抗肿瘤免疫力的提高可能是由于细胞因子在接种部位的持续存在。由于脂质体已被用于多种药物的持续递送，我们比较了由IL-2基因修饰的B16黑色素瘤细胞组成的疫苗与由IL-2脂质体和辐照黑色素瘤细胞组成的疫苗的保护效果。结果表明，两种方法对B16黑色素瘤细胞的致死性攻击具有同等的保护作用。超过20%的受保护动物在接种和/或肿瘤攻击部位出现白癜风。
